{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:25:30Z","timestamp":1774563930764,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40264-020-00932-5","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T15:02:37Z","timestamp":1589641357000},"page":"745-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9298","authenticated-orcid":false,"given":"Linda","family":"H\u00e4rmark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0117-2296","authenticated-orcid":false,"given":"Gerda","family":"Weits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rietje","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-230X","authenticated-orcid":false,"given":"G. Niklas","family":"Nor\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-3224","authenticated-orcid":false,"given":"Florence","family":"van Hunsel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,16]]},"reference":[{"issue":"11","key":"932_CR1","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/BF03261992","volume":"35","author":"S Piening","year":"2012","unstructured":"Piening S, Haaijer-Ruskamp FM, de Graeff PA, Straus SM, Mol PG. Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands. Drug Saf. 2012;35(11):1061\u201372.","journal-title":"Drug Saf"},{"key":"932_CR2","doi-asserted-by":"crossref","unstructured":"Sullivan HW, Aikin KJ, David KT, Berktold J, Stein KL, Hoverman VJ. Consumer understanding of the scope of FDA's prescription drug regulatory oversight: a nationally representative survey. Pharmacoepidemiol Drug Saf. 2019.","DOI":"10.1002\/pds.4914"},{"issue":"1","key":"932_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2165\/00002018-200629010-00007","volume":"29","author":"B Hugman","year":"2006","unstructured":"Hugman B. The Erice declaration : the critical role of communication in drug safety. Drug Saf. 2006;29(1):91\u20133.","journal-title":"Drug Saf"},{"key":"932_CR4","unstructured":"Brabers A, Schors, W. van der, Jong, J. de. (NIVEL). Zorggebruikers zien pati\u00ebntenorganisatie als belangrijke bron voor lotgenotencontact (Healthcare users see patient organization as an important source for contact with fellow patients) 2017 (updated 2017). https:\/\/www.nivel.nl\/nl\/publicatie\/zorggebruikers-zien-patientenorganisatie-als-belangrijke-bron-voor-lotgenotencontact. Accessed 08 Jan 2020."},{"issue":"9629","key":"932_CR5","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/S0140-6736(08)60875-2","volume":"371","author":"S Ayme","year":"2008","unstructured":"Ayme S, Kole A, Groft S. Empowerment of patients: lessons from the rare diseases community. Lancet. 2008;371(9629):2048\u201351.","journal-title":"Lancet"},{"issue":"5","key":"932_CR6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000342758","volume":"3","author":"M Mavris","year":"2012","unstructured":"Mavris M, Le Cam Y. Involvement of patient organisations in research and development of orphan drugs for rare diseases in Europe. Mol Syndromol. 2012;3(5):237\u201343.","journal-title":"Mol Syndromol"},{"issue":"3","key":"932_CR7","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/2168479015622668","volume":"50","author":"G Borup","year":"2016","unstructured":"Borup G, Bach KF, Schmiegelow M, Wallach-Kildemoes H, Bjerrum OJ, Westergaard N. A paradigm shift towards patient involvement in medicines development and regulatory science: workshop proceedings and commentary. Ther Innov Regul Sci. 2016;50(3):304\u201311.","journal-title":"Ther Innov Regul Sci"},{"issue":"4","key":"932_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40264-018-0748-x","volume":"42","author":"C Matos","year":"2019","unstructured":"Matos C, Weits G, van Hunsel F. The role of European patient organizations in pharmacovigilance. Drug Saf. 2019;42(4):547\u201357.","journal-title":"Drug Saf"},{"key":"932_CR9","unstructured":"Nor\u00e9n N, Grundmark, B. Panic attacks with levothyroxine 2017 (updated 2017). https:\/\/apps.who.int\/medicinedocs\/documents\/s23197en\/s23197en.pdf. Accessed 08 Jan 2020."},{"issue":"2","key":"932_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40264-017-0594-2","volume":"41","author":"S Watson","year":"2018","unstructured":"Watson S, Chandler RE, Taavola H, Harmark L, Grundmark B, Zekarias A, et al. Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: results and reflections from Lareb and Uppsala Monitoring Centre. Drug Saf. 2018;41(2):203\u201312.","journal-title":"Drug Saf"},{"key":"932_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/bmb\/ldr030","volume":"99","author":"MP Vanderpump","year":"2011","unstructured":"Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull. 2011;99:39\u201351.","journal-title":"Br Med Bull."},{"key":"932_CR12","unstructured":"Schildklier Organisatie Nederland (SON). Bijwerking van schildkliermedicijn wordt niet altijd herkend. Facebook Post; 2018. https:\/\/www.facebook.com\/schildklier.nl\/ (14\u201312\u20132018, accessed 18\u201312\u20132019)."},{"key":"932_CR13","unstructured":"Schildklier Organisatie Nederland (SON). Bijwerking #schildklier niet altijd herkend. Twitter; 2018 https:\/\/twitter.com\/schildklier\/status\/1073510407489417216?s=19 (14\u201312\u20132018, accessed 18\u201312\u20132019)."},{"key":"932_CR14","unstructured":"Schildklier Organisatie Nederland (SON). Bijwerking schildkliermedicijn niet altijd herkend 2019 (updated 2019). https:\/\/www.schildklier.nl\/nieuws\/43-nieuws\/538-bijwerking-schildkliermedicijn-niet-altijd-herkend. (14\u201312\u20132018, accessed 18\u201312\u20132019)."},{"key":"932_CR15","unstructured":"Schildklier Organisatie Nederland (SON). Magazine Schild. 2018:10\u20131."},{"key":"932_CR16","unstructured":"CBS StatLine. Internet; toegang, gebruik en faciliteiten 2019. https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/83429NED\/table?dl=2F8AA. (09\u201310\u20132019, accessed 09\u201303\u20132020)."},{"key":"932_CR17","unstructured":"Google. Google analytics\u2014measured between December 13, 2018 and January 16, 2019 2019 (updated 16\u201301\u20132019). https:\/\/analytics.google.com\/analytics\/web\/provision\/?authuser=0#\/provision."},{"issue":"8","key":"932_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/dtb.2019.000008","volume":"57","author":"ALJ Freeman","year":"2019","unstructured":"Freeman ALJ. How to communicate evidence to patients. Drug Ther Bull. 2019;57(8):119\u201324.","journal-title":"Drug Ther Bull."},{"key":"932_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1472-6947-14-76","volume":"14","author":"RB Buchter","year":"2014","unstructured":"Buchter RB, Fechtelpeter D, Knelangen M, Ehrlich M, Waltering A. Words or numbers? Communicating risk of adverse effects in written consumer health information: a systematic review and meta-analysis. BMC Med Inform Decis Mak. 2014;14:76.","journal-title":"BMC Med Inform Decis Mak"}],"updated-by":[{"DOI":"10.1007\/s40264-020-00970-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000}}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00932-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00932-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00932-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T22:25:07Z","timestamp":1666563907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00932-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,16]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00932-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40264-020-00970-z","asserted-by":"object"}]},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,16]]},"assertion":[{"value":"16 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article \u201cCommunicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands\u201d, written by Linda H\u00e4rmark, Gerda Weits, Rietje Meijer, Federica Santoro, G. Niklas Nor\u00e9n, Florence van Hunsel, was originally published electronically on 16 May 2020 without open access","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Linda H\u00e4rmark, Gerda Weits, Rietje Meijer, Federica Santoro, G. Niklas Nor\u00e9n and Florence van Hunsel declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"No sources of funding were used to assist in the preparation of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}}]}}